| Ytd | ||
| 1y |
| Open | 1.93 | Prev Close | 1.91 | Low | 1.91 | High | 1.91 | Mkt Cap | N/A |
| Vol | 2.14M | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -0.91 |
| Beta | 1.13 | Short Ratio | 17.89 | Inst. Own | 23.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 6.75 |
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis wit
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis wit
LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE
Durect (DRRX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate
Recent business highlights and updates:In July 2025, DURECT announced that it entered into an Agreem
Bausch Health will pay $1.75 per share plus up to $350 million in aggregate sales milestones Transac
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &
Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating DURECT (NYSE: DRRX) for possible breache
DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designa
DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designa
Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with
DURECT Corporation (NASDAQ:DRRX ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company
Durect (DRRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate
Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AH
CUPERTINO, Calif. , March 19, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage b
CUPERTINO, Calif. , Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced t
The article presents new trial data, including subgroup analyses and liver biomarkers, which have gu
Durect (DRRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about t
AFRM, ZNTL, IMTX, MRCY and DRRX have been added to the Zacks Rank #1 (Strong Buy) List on January 9,
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly los
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares climbed 96% to $0.2921 after falling
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares surged 332% to $0.6455 in pre-market tr
On Wednesday, 311 stocks hit new 52-week lows.
Friday's session saw 112 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
During Tuesday's session, 275 companies made new 52-week lows.
On Thursday, 283 companies set new 52-week lows.
On Tuesday, 164 companies achieved new lows for the year.
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earni
Gainers ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) rose 45% to $0.2890 in pre-market trading after
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 pe
Companies Reporting Before The Bell • Cohen & Co (AMEX:COHN) is likely to report earnings for i
On Tuesday, 31 stocks hit new 52-week lows.
On Wednesday, 258 companies hit new 52-week lows.
Tuesday's session saw 167 companies set new 52-week lows.
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on vol
Gainers
Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesda